An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT05363319
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cemiplimab — DRUG
    solution for injection via intravenous (IV) infusion
  • Platinum-based chemotherapy — DRUG
    IV administration

Study Details

This study is focused on patients with non-small cell lung cancer (NSCLC) and have been prescribed a cemiplimab (Libtayo®) based treatment regimen under standard care. The goal of this study is to learn more about the use, benefits, and safety of cemiplimab based treatment regimens in participants with NSCLC.

Key Dates

Start date
Oct 26, 2022
Status verified
May 2026
Primary completion
Oct 30, 2028
Completion
Oct 30, 2028

Study Design

Enrollment
500 participants (estimated)

Arms

  • Arm: Cohort 1
    Cemiplimab monotherapy
  • Arm: Cohort 2
    Cemiplimab in combination with platinum-based chemotherapy

Primary Outcome Measure

Overall survival (OS) [ Time Frame: Up to 72 months ]

Central Contacts

Related Studies